Taking drugs like LSD and ecstasy can increase your risk of schizophrenia, according to new study
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...
AbbVie's closely watched schizophrenia drug fails two studies, shares slide
AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics ...
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Psychedelics Like Psilocybin, MDMA Tied to Higher Odds for Schizophrenia
Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...
Crain's Chicago Business3d
AbbVie tumbles after new schizophrenia drug fails trials
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
pharmaphorum3d
Advantage BMS as AbbVie drug fails schizophrenia trials
If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...
Ottawa Citizen on MSN1d
Study finds 'concerning link' between hospital visits for psychedelic use and schizophrenia
The research, led by Dr. Daniel Myran, a Canada Research Chair in Social Accountability at the University of Ottawa, followed ...
BioPharma Dive3d
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Yahoo Finance4d
AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
Bristol Surges AbbVie’s setback was viewed as a victory for Bristol Myers Squibb Co., which in late September gained US approval for the first new type of schizophrenia drug in seven decades.
Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...